Blood

Vol. 146, Issue 16 Issue 16 2025
20
Articles

Articles in this Issue

Shomali W. An adaptive survival prediction model in CMML. <i>Blood.</i> 2025;146(7):775-777.

Oct 16, 2025 pp. 2006-2006 10.1182/blood.2025031469

Clinical presentation, management, and outcome of TIAN in CNS lymphoma treated with CD19-CAR T-cell therapy

Leon D. Kaulen, Maria Martinez-Lage, Jeremy S. Abramson et al. Oct 16, 2025 pp. 1902-1913 10.1182/blood.2025028964

Abstract Tumor inflammation-associated neurotoxicity (TIAN) was recently proposed as a unique complication of immunotherapy in patients with brain tumor. Here, we report a first comp...

CD99 promotes self-renewal in hematopoietic stem cells and leukemia stem cells by regulating protein synthesis

Yuanyuan Ji, Yi Huang, Toby Thomas et al. Oct 16, 2025 pp. 1914-1928 10.1182/blood.2024026271

Abstract Blood production is sustained by hematopoietic stem cells (HSCs), which are typically the only blood cells capable of long-term self-renewal. HSCs exhibit and depend on low...

Safety and efficacy of elranatamab in patients with relapsed and/or refractory immunoglobulin light-chain amyloidosis

Pedro Vianna, Rajshekhar Chakraborty, Shahrier Hossain et al. Oct 16, 2025 pp. 1929-1935 10.1182/blood.2025028383

Abstract Immunoglobulin light-chain (AL) amyloidosis is a plasma cell disorder characterized by progressive organ dysfunction secondary to deposition of organized immunoglobulin ligh...

Acute myeloid leukemia mimicking mature lymphoid morphology

Radu Chiriac Oct 16, 2025 pp. 2005-2005 10.1182/blood.2025030253

Shaping individualized care for women with hemophilia A

Maria Elisa Mancuso Oct 16, 2025 pp. 1880-1881 10.1182/blood.2025030645

CD99 tunes translation to sustain stem cells

Kaosheng Lv, Wei Tong Oct 16, 2025 pp. 1872-1873 10.1182/blood.2025030492

BCMA: BeCoMing a new hope for AL amyloidosis

Efstathios Kastritis Oct 16, 2025 pp. 1874-1875 10.1182/blood.2025030526

Remestemcel-L-rknd (Ryoncil): the first approved cellular therapy for steroid-refractory acute GVHD

Aaron Etra, James L. M. Ferrara, John E. Levine Oct 16, 2025 pp. 1897-1901 10.1182/blood.2025028553

Abstract Until recently, the JAK1/2 inhibitor ruxolitinib (Jakafi) was the only therapy for steroid-refractory acute graft-versus-host disease approved by the US Food and Drug Admini...

Casein kinase 1α essentially regulates thrombopoiesis by driving megakaryocyte maturation and cytoskeleton organization

Ferdinand Kollotzek, Kristina Mott, Melina Fischer et al. Oct 16, 2025 pp. 1964-1978 10.1182/blood.2025028460

Abstract Throughout thrombopoiesis megakaryocytes (MKs) form proplatelets within the bone marrow (BM) and release platelets into BM sinusoids. Casein kinase 1α (CK1α) is a major play...

LocaTIAN, locaTIAN, locaTIAN

Juliane Gust, Liora M. Schultz Oct 16, 2025 pp. 1871-1872 10.1182/blood.2025030292

How many NOTCHes (activation pathways) are there in CLL?

Federico Pozzo, Valter Gattei Oct 16, 2025 pp. 1876-1877 10.1182/blood.2025030461

Impaired cytotoxic function and exhausted phenotype of natural killer cells in VEXAS syndrome

Paul Breillat, Francesco Carbone, Emilie Lereclus et al. Oct 16, 2025 pp. 1950-1963 10.1182/blood.2024028216

Abstract VEXAS (vacuoles, E1 enzyme, X-linked, autoinflammatory, somatic) syndrome is an autoinflammatory disorder caused by acquired somatic ubiquitin like modifier activating enzym...

Gene variants influence the response to desmopressin

Oct 16, 2025 pp. 2007-2007 10.1182/blood.2025031511

NK cell exhaustion in VEXAS: another piece in the puzzle

Corrado Campochiaro, Roger Belizaire Oct 16, 2025 pp. 1877-1878 10.1182/blood.2025030330

<i>F8</i> gene variants influence the response to desmopressin in hemophilia A carriers

Benoît Guillet, Roseline d’Oiron, Marc Trossaërt et al. Oct 16, 2025 pp. 1991-2004 10.1182/blood.2025029829

Abstract Desmopressin (DDAVP) is often administered to correct factor VIII (FVIII) levels in female hemophilia A carriers (HACs). However, the post-DDAVP FVIII pharmacokinetic profil...

A noncoding mutation in the <i>NOTCH1</i> gene initiates oncogenic NOTCH signaling via wild-type NICD stabilization in CLL

Min Guo, Tugba Memis, Alena Sophie Ehrmann et al. Oct 16, 2025 pp. 1936-1949 10.1182/blood.2025028529

Abstract Chronic lymphocytic leukemia (CLL) is the most common chronic blood cancer in adults. Active NOTCH signaling in CLL is associated with poorer prognosis. Importantly, patient...

A precision medicine approach to the myelodysplastic syndrome with isolated deletion 5q, 50 years after its discovery

Marco Roncador, Elsa Bernard, Robert Hasserjian et al. Oct 16, 2025 pp. 1883-1896 10.1182/blood.2025028619

Abstract In 1974, Van den Berghe et al described a distinct hematologic disorder associated with acquired, interstitial deletion of part of the long arm of chromosome 5. This conditi...

Of mice, men, and megakaryocytes: CK1α governs thrombopoiesis

Meenakshi Banerjee, Matthew T. Rondina Oct 16, 2025 pp. 1879-1880 10.1182/blood.2025030355

The interleukin-33 receptor (ST2) is a novel therapeutic target to attenuate the progression of hemophilic arthropathy

Heike C. Hawerkamp, Aoife Yeow, Ciara M. Byrne et al. Oct 16, 2025 pp. 1979-1990 10.1182/blood.2024027578

Abstract Hemophilia A is an X-linked bleeding disorder caused by a blood clotting protein factor VIII deficiency. Patients with hemophilia develop recurrent bleeding episodes. When b...

All Issues

Journal Info

Publisher Elsevier BV
ISSN 0006-4971
E-ISSN 1528-0020
Subject Health Sciences
Language English
View Full Journal Page